Genmab (ADR) (GMAB)
Develops antibody medicines through partner royalties, co-commercialization, and a wholly owned oncology portfolio.
$35.41
vs last close+0.19 (+0.54%)
Something off on this page? Send us feedback.
Next report
Nov 5, 26
in 43 days
EPS estimate
$0.37
Revenue estimate
$1.21B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$0.57$0.31$0.54$0.65$0.05$0.09$0.54Pending
Estimate$0.36$0.23$0.39$0.48$0.46$0.15$0.37$0.37
Surprise+58.3%+34.8%+38.5%+35.4%−89.1%−42.0%+45.9%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$895.8M$726.0M$924.8M$1.02B$1.06B$896.0M$1.16BPending
Estimate$894.7M$755.5M$952.6M$1.01B$1.07B$905.8M$1.12B$1.21B
Surprise+0.1%−3.9%−2.9%+1.1%−0.8%−1.1%+3.5%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $0.79 | — | — |
| Sep 2028 | $0.72 | — | — |
| Jun 2028 | $0.72 | — | — |
| Mar 2028 | $0.31 | — | — |
| Dec 2027 | $0.57 | — | — |
| Sep 2027 | $0.49 | — | — |
| Jun 2027 | $0.43 | — | — |
| Mar 2027 | $0.20 | — | — |
| Dec 2026 | $0.31 | — | — |
| Nov 2026 | $0.37 | — | — |
| Aug 2026 | $0.37 | $0.54 | +45.9% |
| May 2026 | $0.15 | $0.09 | −42.0% |
| Feb 2026 | $0.46 | $0.05 | −89.1% |
| Nov 2025 | $0.48 | $0.65 | +35.4% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Dec 2017 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| Jun 2016 | |||
| Mar 2016 | |||
| Dec 2015 | |||
| Sep 2015 | |||
| Jun 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $0.79 | — | — | $1.71B | — | — | — |
| Sep 2028 | $0.72 | — | — | $1.58B | — | — | — |
| Jun 2028 | $0.72 | — | — | $1.53B | — | — | — |
| Mar 2028 | $0.31 | — | — | $1.17B | — | — | — |
| Dec 2027 | $0.57 | — | — | $1.45B | — | — | — |
| Sep 2027 | $0.49 | — | — | $1.34B | — | — | — |
| Jun 2027 | $0.43 | — | — | $1.28B | — | — | — |
| Mar 2027 | $0.20 | — | — | $1.06B | — | — | — |
| Dec 2026 | $0.31 | — | — | $1.24B | — | — | — |
| Nov 5, 2026 | $0.37 | — | — | $1.21B | — | — | — |
| Aug 6, 2026 | $0.37 | $0.54 | +45.9% | $1.12B | $1.16B | +3.5% | +2.0% |
| May 7, 2026 | $0.15 | $0.09 | −42.0% | $905.8M | $896.0M | −1.1% | −3.0% |
| Feb 17, 2026 | $0.46 | $0.05 | −89.1% | $1.07B | $1.06B | −0.8% | −0.1% |
| Nov 6, 2025 | $0.48 | $0.65 | +35.4% | $1.01B | $1.02B | +1.1% | −1.2% |
| Aug 7, 2025 | |||||||
| May 8, 2025 | |||||||
| Feb 12, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 2, 2024 | |||||||
| Feb 14, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 10, 2023 | |||||||
| Feb 22, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 10, 2022 | |||||||
| May 11, 2022 | |||||||
| Feb 16, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 11, 2021 | |||||||
| May 5, 2021 | |||||||
| Feb 23, 2021 | |||||||
| Nov 4, 2020 | |||||||
| Aug 12, 2020 | |||||||
| May 6, 2020 | |||||||
| Feb 19, 2020 | |||||||
| Nov 6, 2019 | |||||||
| Aug 20, 2019 | |||||||
| Mar 31, 2019 | |||||||
| Dec 31, 2018 | |||||||
| Sep 30, 2018 | |||||||
| Jun 30, 2018 | |||||||
| Mar 31, 2018 | |||||||
| Dec 31, 2017 | |||||||
| Sep 30, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Dec 31, 2016 | |||||||
| Sep 30, 2016 | |||||||
| Jun 30, 2016 | |||||||
| Mar 31, 2016 | |||||||
| Dec 31, 2015 | |||||||
| Sep 30, 2015 | |||||||
| Jun 30, 2015 |